Antares Pharma, Inc.
161 Cheshire Lane
Suite 100
Plymouth
Minnesota
55441
United States
Tel: 800-328-3074-or-612-475-7700
Fax: 612-476-1009
Website: http://www.antarespharma.com/
371 articles about Antares Pharma, Inc.
-
Halozyme Completes Antares Pharma Acquisition
5/24/2022
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced the successful completion of its acquisition of Antares Pharma, Inc. (" Antares ").
-
Halozyme Commences Tender Offer For All Outstanding Shares Of Common Stock Of Antares Pharma
4/26/2022
Halozyme Therapeutics, Inc. announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc., a cash tender offer to purchase all outstanding shares of common stock of Antares Pharma, Inc. for $5.60 per share in cash.
-
FDA Approves TLANDO® (testosterone undecanoate), an Oral Treatment for Testosterone Replacement Therapy by Antares Pharma, Inc., developed by Lipocine Inc.
4/25/2022
Brand Institute is proud to announce working with Lipocine Inc. in developing the brand name TLANDO®, approved by the Food and Drug Administration (FDA) on March 28, 2022.
-
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
4/13/2022
Halozyme Therapeutics, Inc. and Antares Pharma, Inc. announced that the companies have entered into a definitive agreement pursuant to which Halozyme will acquire Antares for $5.60 per share in cash.
-
Halozyme Therapeutics announced that it is acquiring Antares Pharma for $960 million in cash. The news caused Antares stock to rocket 47% in premarket trading.
-
Antares Pharma has announced that the U.S. Food and Drug Administration has granted approval to its therapeutic Tlando intended for testosterone replacement therapy (TRT).
-
Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy Commercial launch expected in 2Q 2022
3/29/2022
Antares Pharma, Inc. today announced that the U.S. Food and Drug Administration granted final approval for TLANDO™ (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”) indicated for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult males.
-
The FDA has a very busy week ending the month of March and moving into April, highlighted by a big AdCom vote on Amylyx's ALS candidate AMX0035 on March 30.
-
Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results
3/3/2022
Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record revenue of $48.7 million, net income of $32.7 million, or $0.19 per diluted earnings per share, and adjusted net income of $4.1 million, or $0.02 per adjusted diluted earnings per share, which excludes the gain on the sale of OTREXUP®.
-
Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference
2/28/2022
Antares Pharma, Inc. today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Cowen 42nd Annual Healthcare Conference being held on March 7-9, 2022.
-
Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results
2/17/2022
Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens.
-
Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®PDUFA target action date set for March 28, 2022
2/3/2022
Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its New Drug Application (“NDA”) resubmission for TLANDO® (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”).
-
Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue
1/18/2022
Antares Pharma, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for ATRS-1902 for adrenal crisis rescue.
-
Antares Pharma Appoints Claude E. Richardson as Senior Vice President of Human Resources
1/12/2022
Antares Pharma, Inc., a specialty pharmaceutical company, announced the appointment of Claude E. Richardson as Senior Vice President of Human Resources.
-
Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
1/11/2022
Antares Pharma, Inc. today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis.
-
Assertio Holdings, Inc. Announces the Acquisition of Otrexup® (methotrexate) a Drug Device Combination from Antares Pharma, Inc.
12/15/2021
Assertio Holdings, Inc., a leading commercial pharmaceutical company bringing differentiated products to patients, announced it has acquired Otrexup, a drug device combination single dose once weekly auto-injector, from Antares Pharma, Inc. in the Company’s first new product acquisition since 2015.
-
Antares Pharma Announces Divestiture of Otrexup®
12/15/2021
Antares Pharma, Inc., a specialty pharmaceutical company, announced the divestiture of OTREXUP® injection for the treatment of rheumatoid arthritis to a subsidiary of Assertio Holdings, Inc., a commercial pharmaceutical company, for a total cash consideration of $44.0 million inclusive of OTREXUP® WIP and finished inventory.
-
Antares Pharma to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
11/22/2021
Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021.
-
Antares Pharma to Present at the Jefferies London Healthcare Conference
11/10/2021
Antares Pharma, Inc., a specialty pharmaceutical company, announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Jefferies London Healthcare Conference being held November 16-19, 2021.
-
Antares Pharma Reports Third Quarter 2021 Financial and Operating Results
11/4/2021
Antares Pharma, Inc., a specialty pharmaceutical company, reported financial and operating results for the third quarter ended September 30, 2021 with record revenue of $48.2 million and net income of $5.4 million, or $0.03 per basic and diluted earnings per share.